Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

NEW
NAS:NTLA (USA)  
$ 8.15 -0.24 (-2.92%) 11:05 AM EST
At Loss
P/B:
0.95
Market Cap:
$ 844.18M
Enterprise V:
$ 479.26M
Volume:
731.75K
Avg Vol (2M):
3.25M
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
731.75K
At Loss
Avg Vol (2M):
3.25M

Business Description

Description
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Financials (Next Earnings Date:2025-05-09 Est.)

NTLA's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NTLA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Intellia Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 57.877
EPS (TTM) ($) -5.25
Beta 1.8
3-Year Sharpe Ratio -1.06
3-Year Sortino Ratio -1.24
Volatility % 50.33
14-Day RSI 38.64
14-Day ATR ($) 0.736767
20-Day SMA ($) 9.2755
12-1 Month Momentum % -59.81
52-Week Range ($) 8.105 - 28.23
Shares Outstanding (Mil) 103.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Intellia Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Intellia Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Intellia Therapeutics Inc Frequently Asked Questions

What is Intellia Therapeutics Inc(NTLA)'s stock price today?
The current price of NTLA is $8.15. The 52 week high of NTLA is $28.23 and 52 week low is $8.11.
When is next earnings date of Intellia Therapeutics Inc(NTLA)?
The next earnings date of Intellia Therapeutics Inc(NTLA) is 2025-05-09 Est..
Does Intellia Therapeutics Inc(NTLA) pay dividends? If so, how much?
Intellia Therapeutics Inc(NTLA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1